Learn languages naturally with fresh, real content!

tap to translate recording

Explore By Region

flag Tardive dyskinesia often goes untreated in long-term care, with many misdiagnosed, Teva study shows.

flag Teva Pharmaceuticals' recent study at Psych Congress Elevate 2025 revealed that over half of long-term care residents with tardive dyskinesia (TD) do not receive proper treatment, and one-quarter receive no treatment at all. flag The research also found that these patients are often misdiagnosed with extrapyramidal syndrome, leading to incorrect treatment. flag Teva plans further research into the unmet needs of TD patients in long-term care settings.

7 Articles